Oct 16 (Reuters) - Pfizer Inc said on Friday it would apply for emergency use in the United States of its COVID-19 vaccine candidate being developed along with Germany’s BioNTech SE as soon as a safety milestone is achieved in the third week of November. (Reporting by Manojna Maddipatla in Bengaluru Editing by Saumyadeb Chakrabarty)
Our Standards: The Thomson Reuters Trust Principles.